Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Hiv Drug Resistance Among Naive Hiv-Infected Patients in Iran Publisher



Farrokhi M1 ; Gholami M1, 2 ; Mohraz M1 ; Mcfarland W3 ; Baesi K4 ; Abbasian L1, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, P.O. Box 14115-561, Tehran, Iran
  2. 2. Department of Medical Microbiology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
  3. 3. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, United States
  4. 4. Department of Hepatitis and AIDS, Pasteur Institute of Iran, P.O. Box 14115-331, Tehran, Iran
  5. 5. Department of Infectious Diseases and Tropical Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Research in Medical Sciences Published:2019


Abstract

Background: Antiretroviral (ARV) therapy extends life for persons living with HIV. Antiretroviral treatment (ART) has been rapidly expanding coverage around the world, including in Iran. However, ART drug resistance also rapidly develops with expanding use and limits effectiveness and treatment options. The aim of this study was to monitor the appearance of new mutations conferring HIV pretreatment drug resistance in the treatment of naive patients with HIV in Iran. Materials and Methods: Blood samples were obtained from ARV treatment-naive patients from 8 different provinces in Iran in 2016 for genotyping for drug resistance mutations. Results: Sequences were successfully obtained from 90 specimens. Of these, 2 (2%) mutations conferring resistance to protease inhibitors, 2 (3%) conferring resistance to nucleoside reverse transcriptase inhibitors (NRTIs), and 9 (13%) conferring resistance to non-NRTI (NNRTI) were detected. Any ARV-resistant drug mutation was found in 11 patients (12%). Conclusion: Nearly one in 8 ARV-naive patients had mutations associated with NNRTI resistance in diverse areas of Iran in 2016. Iranian ARV therapy guideline for HIV could consider non-NNRTI-based first-line therapies and expand routine drug resistance testing before treatment initiation as according to HIV drug resistance recommendations of the World Health Organization. © 2019 Journal of Research in Medical Sciences.
Related Docs
View other Related Docs
1. Transmitted Drug Resistance Mutations in Antiretroviral-Naive Injection Drug Users With Chronic Hiv-1 Infection in Iran, PLoS ONE (2015)
2. Antiretroviral Drug Resistance Mutations in Naive and Experienced Patients in Shiraz, Iran, 2014, Archives of Virology (2016)
3. Hiv Drug Resistance and Phylogeny Profile in Naive and Antiretroviral-Experienced Patients in Tehran, Iran, Intervirology (2017)
4. Antiretroviral Drug Resistance Mutations Among Hiv Treatment Failure Patients in Tehran, Iran, Iranian Journal of Public Health (2017)
5. Crf35-Ad As the Main Circulating Genotype of Human Immunodeficiency Virus Type 1 Infection in Iran: A Phylogenetic and Demographic-Based Study, Intervirology (2018)
6. Phylogeny and Drug Resistance of Hiv Pr Gene Among Hiv Patients Receiving Rt Inhibitors in Iran, Asian Pacific Journal of Tropical Biomedicine (2016)
7. Hiv-1 Drug Resistance Mutations Among Antiretroviral Drug-Experienced Patients in the South of Iran, Intervirology (2019)
8. Evaluation of Ccr5-I32 Mutation and Hiv-1 Surveillance Drug-Resistance Mutations in Peripheral Blood Mononuclear Cells of Long-Term Non Progressors of Hiv-1-Infected Individuals, Future Virology (2022)
Experts (# of related papers)
View all Related Experts
Ladan Abbasian (1)
Reza Shirkoohi (1)
Other Related Docs
9. Evaluation of Acquired Hiv Drug Resistance Among People Living With Hiv Who Have Taken Antiretroviral Therapy for 9-15 Months in 14 Triangular Clinics in Iran, 2015-2016, Intervirology (2019)